Create a free Cannabis Business Times account to continue reading

Continue to Site »
Site will load in 15 seconds

Trulieve Approved to Uplist on New York Stock Exchange

The company announced its subordinate voting shares are expected to begin trading under the ticker ‘TRLV’ on June 10 on the NYSE.

Trulieve Logo
Trulieve Cannabis Corp.

[PRESS RELEASE] – TALLAHASSEE, Fla., June 5, 2026 – Trulieve Cannabis Corp., a leading and top-performing medical cannabis company in the U.S., announced that its subordinate voting shares have been approved for listing on the New York Stock Exchange (NYSE). The subordinate voting shares are expected to begin trading on the NYSE under the symbol "TRLV" at the opening of trading on June 10, 2026.

"As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity and raise awareness for the benefits of medical marijuana,” Trulieve founder and CEO Kim Rivers said. “Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone. Uplisting to the NYSE is a major advancement for Trulieve and the industry."

Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III in April 2026, following an executive order by Trump in December 2025. The final order issued in April rescheduled state-licensed medical marijuana products and created a pathway for Drug Enforcement Administration (DEA) registration for state-licensed medical marijuana businesses under the treaty authority pursuant to the United Nations Single Convention on Narcotic Drugs.

Following medical marijuana rescheduling, Trulieve completed a corporate restructuring and investment by a third party resulting in the deconsolidation of operations in markets serving both medical and adult-use customers. Trulieve's remaining consolidated operations consist only of state-licensed medical marijuana facilities and include 206 medical marijuana dispensaries supported by 3.5 million square feet of production capacity registered with the DEA.

"Since inception, Trulieve has focused on serving medical patients with compassion, care and high-quality products," Rivers said. "With robust cash generation and meaningful catalysts ahead, including expansion in Georgia and Texas, Trulieve is well-positioned to deliver on our promise to increase access to medical cannabis for U.S. patients."

The company anticipates the subordinate voting shares will continue trading on the Canadian Securities Exchange (CSE) under the symbol "TRUL" and the OTCQX under the symbol "TCNNF" until the close of market on June 9, 2026. Current shareholders of the company do not need to take any action prior to the company's expected listing on the NYSE.

Page 1 of 198
Next Page